AKT1 and breast cancer: DDR1 depletion inhibits cell growth and cell cycle progression and enhances the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib in estrogen receptor (ER)-positive, HER2-negative breast cancer [33].